Some Products May Appear Restricted
To ensure a smooth and speedy checkout, please log in to your account. Some items may show as restricted simply because you're not logged in.
If you do not have an account, you can register using our registration webform (https://www.avantorsciences.com/us/en/login/register)
If you're still seeing restrictions after logging in, certain products—like chemicals or medical devices—require additional account verification steps to be able to place an order. Some items may additionally require a specific license or customer documentation; additional documentation will be requested for these items prior to shipment.
Specifications
- Target protein:Anti-GP 2 (Glycoprotein 2)IgG
- Description:Anti-GP 2 (Glycoprotein 2)IgG ELISA
- Size:1 kit
- Cat. No.:102993-394
- Supplier no.:G2G31-K01
Specifications
About this item
Anti-GP2 IgG determines IgG antibodies against glycoprotein 2 in human serum.
- Dynamic Range: 1 - 300 U/ml
- Sensitivity: 1 U/mL
- Incubation: 1.5 hours
Non-specific inflammatory bowel disease including Crohn’s disease (Enteritis regionalis) and ulcerative colitis (UC) are characterised by unknown etiology as well as chronic-remitting inflammatory processes of the intestine. Whereas the inflammation of ulcerative colitis is restricted to the mucosa and submucosa of colon and rectum, Crohn’s disease (CD) shows a wide spread inflammation of gastro-intestinal tract with granuloma formation. The risk developing one of these diseases is strongly correlated to immunologic, genetic, infectious and environmental factors. The differential diagnosis of inflammatory bowel diseases to chronic diarrhea, recurrent abdominal dolor, infectious colitis, anorexia as well as the differentiation of CD to UC is still a challenge. Autoantibodies of exocrine pancreas (PAB) were identified as specific serological marker for CD. A prevalence of 39 % of these autoantibodies in patients with CD could be demonstrated by indirect immune fluorescence (Stöcker et al. 1987). Glycoprotein 2 (GP2), a membrane-bound pancreatic protein, could be identified/verified as the major target of PAB’s (Roggenbuck et al., 2009). In combination with the detection of autoantibodies to Saccharomyces cerevisiae (ASCA) with a prevalence of 70 % in patients with CD and atypical antineutrophile cytoplasmatic Antigenss (aANCA) which are mainly found in patients with UC, PAB’s against GP2 could be used as a highly specific serological marker for differential diagnosis of CD to UC.